These studies suggest that STAT5 signaling is a potentially attractive therapeutic target in high-risk B-ALL [3, 9, 20, 21]; however, targeted small molecule inhibitors of STAT5 are not currently available. Here, STAT5A is linked to precursor B-cell acute lymphoblastic leukemia.